During the study period, 721 eligible episodes were identified, and data on the susceptibility to 24 cefotaxime was obtainable for 690 episodes. Sixty six (10%) cases were due to a cefotaxime non-25 susceptible strain with a 30-day mortality rate of 8%. Variables associated with 30-day mortality
Introduction
antimicrobial resistance, cefotaxime and ceftriaxone remain the most active cephalosporins [9] . To date, however, the clinical impact of third-generation cephalosporins (3GC) non-susceptibility on 46 clinical outcomes has not been comprehensively evaluated in cases of pneumococcal bacteremic pneumonia.
48
In the present study, we aimed to analyze the effect of 3GC non-susceptibility on the outcomes 49 of patients with bacteremic pneumococcal pneumonia treated empirically with a third-generation 50 cephalosporin. 
Study design and patients

57
This was a retrospective observational study of data that were prospectively collected at the 58 Hospital Clinic of Barcelona. All adult patients with monomicrobial bacteremic pneumonia due to S.
59
pneumoniae admitted to the hospital between January 1991 and December 2016 were included. We 
Data collection and evaluation
63
The following data were obtained from all patients: age, gender, comorbidities, McCabe score
64
[10], Pneumonia Severity Score (PSI) 
77
Prior antimicrobial therapy was defined as the use of any antimicrobial agent for at least 3 days 78 during the month before the onset of bacteremia. Prior steroid therapy was defined as the use of at 79 least 10 mg of prednisone (or equivalent dose of another steroid) during the month before admission.
80
Septic shock was defined as a systolic blood pressure <90 mmHg, peripheral hypoperfusion, and use
81
of vasopressors for >4 h after initial fluid replacement [12] . The most widely used third-generation 82 cephalosporin in our institution (>90%) is ceftriaxone and the standard dose is 1g q24h for non-
83
critically ill patients and 2 g q24h for critically ill patients.
84
Microbiological evaluation and diagnostic criteria
85
During the study period, blood cultures were processed using a BACTEC 9240 system (Becton 
114
pneumoniae strains during the study is shown in Figure 1 . 
124
We identified that 66 cases (10%) were due to a 3GC non-susceptible S. pneumoniae. Notably, the 125 prevalence of these strains did not change significantly over time (p = 0.75) (Figure 2 ). The 126 characteristics of patients according to 3GC susceptibility are shown in Table 1 
222
The main limitation of our study is that the number of patients with non-susceptible strains was 
Conclusion
230
In conclusion, we found no evidence to suggest that patients hospitalized for 3GC non- 
